<DOC>
	<DOCNO>NCT02225574</DOCNO>
	<brief_summary>The goal clinical research study find high tolerate dose combination nilotinib MEK-162 give patient CML acute leukemia . Researchers also want learn drug combination help control disease . The safety drug combination also study .</brief_summary>
	<brief_title>An Open-Label , Phase I/II Study Nilotinib ( Tasigna ) MEK-162 ( ARRY-162 ) Used Combination Patients With Refractory Advanced Chronic Myeloid Leukemia Philadelphia Positive Acute Leukemia ( Protocol CAMN107AUS41T )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group base join study . Up 5 group 6 participant enrol Phase 1 study , 60 participant enrol Phase 2 . If enrolled Phase 1 , dose nilotinib MEK-162 receive depend join study . The first group participant receive start dose combination level . The next group receive high dose MEK-162 Group 1 , intolerable side effect see . If intolerable side effect see , next group may receive low dose level nilotinib and/or MEK-162 . This continue high tolerable combination dose find . If enrolled Phase 2 , receive nilotinib MEK-162 high dose tolerate Phase 1 . Study Treatment : You take nilotinib MEK-162 two time every day mouth . Participants enrol Phase 1 study start take MEK-162 Day 1 nilotinib Day 2 . Participants Phase 2 study divide 2 group : one group start MEK-162 Day 1 nilotinib Day 2 , group start MEK-162 Day 1 nilotinib Day 8 . You place Phase 2 treatment group base characteristic disease type . You give drug diary ask write time take study drug every day . Bring unused study drug bottle study visit . Each cycle 28 day . If disease appear get good 1 3 cycle , may able receive high dose study drug long already receive high dose plan study . The study doctor tell receive high dose . Study Visits : On Days 1 8 Cycle 1 : - You physical exam . - Blood ( 2-3 tablespoon ) urine collect routine test . - You EKG . At end Cycle 1 : - You physical exam . - Blood ( 2-3 tablespoon ) urine collect routine test . - You EKG either MUGA scan ECHO . - You complete questionnaire feeling . - If doctor think need , bone marrow aspirate check status disease . At end Cycles 2 , 3 , every 3 cycle ( 6 , 9 , 12 , ) : - You physical exam . - Blood ( 2-3 tablespoon ) urine collect routine test . - You EKG . - You complete questionnaire feeling . At end Cycles 2 , 3 , 6 , 9 , 12 , blood ( 3-4 tablespoon time ) drawn test check disease respond therapy . If doctor think need , test may perform often . Every 8-12 week , MUGA scan ECHO . You eye exam eye doctor end Cycles 2 , 3 , 6 , 9 , 12 , every 3 month End Study Visit . You blood draws and/or bone marrow aspiration time doctor think need study . Length Study : You take 12 cycle nilotinib MEK-162 study . If disease responds certain way ( call hematological response ) study , may able continue take study drug longer 12 month , long doctor think benefit treatment . Even disease respond way , may able continue take study drug doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . End-of-Study Visit : If come study end Cycle 12 , follow test procedure perform : - You physical exam . - Blood ( 2-3 tablespoon ) urine collect routine test . - You EKG either ECHO MUGA scan . - You eye exam eye doctor . - You complete questionnaire feeling . - If doctor think need , bone marrow aspirate check status disease . If come study end Cycle 12 , End Study visit . Follow-Up : You call 30 day go study ask side effect and/or new treatment ( ) . This call last 5 minute . This investigational study . Nilotinib FDA approve commercially available treat CML philadelphia-positive acute leukemia . MEK-162 FDA approve commercially available . It currently use research purpose . The combination nilotinib MEK-162 treat CML Philadelphia-positive acute leukemia investigational . The study doctor explain study drug design work . Up 90 patient take part study . All enrol MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Patients 18 year age old advanced CML ( CMLAP , CMLBP Philadelphia chromosomepositive acute leukemia ) refractory chronic phase CML eligible , define follow : The phase I portion study conduct first advanced phase ( accelerated phase CML , blast phase CML Philadelphiapositive acute leukemia ) patient . Once MTD identify , cohort 6 patient CML chronic phase fail prior therapy least two tyrosine kinase inhibitor treat MTD determine dose also acceptable chronic phase patient . The phase II conduct two treatment arm follow : Treatment Arm A ( Advanced phase disease ) treatment Arm B ( Therapy CPCML refractory/resistant/suboptimally respond least two prior TKI 's ) 2 . ( Cont Inclusion Criteria # 1 ) CMLAP define presence one following : . 1529 % blast peripheral blood ( PB ) bone marrow ( BM ) , b. &gt; 20 % basophil PB BM , c. &gt; 30 % blast plus promyelocytes ( blast &lt; 30 % ) PB BM , d. &lt; 100 x109/L platelet unrelated therapy , Clonal cytogenetics evolution ( i.e. , presence cytogenetic abnormality Philadelphia chromosome ) except present time diagnosis associate feature accelerate phase . CMLBP define presence &gt; /=30 % blast bone marrow and/or peripheral blood presence extramedullary disease , myeloid lymphoid blast morphology . Philadelphiachromosome acute leukemia eligible define &gt; /=20 % blast peripheral blood bone marrow time diagnosis . 3 . Patients advanced phase CML acute leukemia must fail least one prior TKI . Patients chronic phase CML must fail , resistance suboptimal response least two tyrosine kinase inhibitor , intolerance two prior tyrosine kinase inhibitor . For patient prior intolerance , receive least 2 TKI experience intolerance one TKI resistance/suboptimal 4 . ( Cont Inclusion Criteria # 3 ) . Failure tyrosine kinase inhibitor define per EuropeanLeukemiaNet ( ELN ) recommendation b.Resistance suboptimal response least two prior Ablkinase inhibitor , specifically : i.Chronicphase resistance imatinib , dasatinib , nilotinib , bosutinib ponatinib define 1 . Loss CCyR time failure achieve CCyR &gt; /=18 month 2 . Loss MCyR time failure achieve PCyR &gt; /=12 month 3 . Failure achieve CyR ( ie , &gt; /= 65 % Ph+ ) &gt; /= 6 month 4 . Hematologic relapse failure achieve CHR &gt; /=3 month ii . Chronicphase suboptimal response imatinib , define 1 . Failure achieve PCyR &gt; /= 6 month 2 . Failure achieve CCyR &gt; /=12 month iii . Chronicphase suboptimal response nilotinib , bosutinib , dasatinib ponatinib , define 1 . Failure achieve PCyR &gt; /= 3 month 2 . Failure achieve CCyR &gt; /= 6 month therapy 5 . Patients cytogenetic BCRAbl variant additional chromosomal abnormality ( 'clonal evolution ' ) eligible . Cytogenetics perform , result require start therapy patient hematologic progression 6 . Patients fail nilotinib , include refractory nilotinib dose relapse nilotinib dose eligible study . Patients currently nilotinib continue prescribe dose nilotinib MEK162 add base current cohort level phase I establish MTD phase II . In instance nilotinib dose great current cohort ( phase 1 ) MTD ( phase 2 ) patient dose reduce dosage prescribe protocol dose escalate allow protocol PIs discretion . 7 . For phase I portion study , patient receive prior therapy nilotinib able tolerate dose equivalent start dose nilotinib dose level patient enter . Patients previously receive nilotinib never dose propose eligible provide tolerated maximum dose prescribe grade 3 4 toxicity respond optimal management . 8 . Patients must prior therapy CML 2 week prior start study therapy recover toxic effect therapy . Exceptions hydroxyurea TKIs ( include limit imatinib , nilotinib , dasatinib , ponatinib bosutinib ) , discontinue â‰¥48 hr prior start therapy . Patients receive nilotinib prior enrollment discontinue agent prior start study therapy 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /=2 10 . Men woman childbearing potential practice effective method contraception . Men woman childbearing potential define : male surgically sterilize female amenorrheic least 12 consecutive month surgically sterilize . Patients must use birth control study 3 month last dose study drug sexually active . 11 . Adequate organ function : Serum creatinine &lt; /=2.0 mg/dl creatinine clearance &gt; /=60 mL/min , Direct bilirubin &lt; /=2.0xULN ( unless consider due leukemia involvement ) , Alanine aminotransferase ( ALT ) &lt; /=2.5xULN ( &lt; /=5.0xULN consider due leukemic involvement . ) 12 . Adequate cardiac function : leave ventricular ejection fraction ( LVEF ) &gt; /= 50 % determine multigated acquisition ( MUGA ) scan echocardiogram , QTc interval &lt; /= 480 m ; 13 . Women childbearing potential must pregnancy test screening . 14 . Signed informed consent . 1 . Impaired cardiac function include one following : . Inability monitor QT interval ECG b. Congenital long QT syndrome know family history long QT syndrome . c. Clinically significant rest brachycardia ( &lt; 45 beat per minute ) d. QTc &gt; 480 msec baseline ECG . If QTc &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc e. Impaired cardiovascular function clinically significant cardiovascular disease , include follow : History acute coronary syndrome ( include myocardial infarction , unstable angina , coronary artery bypass grafting , coronary angioplasty , stenting ) &lt; 6 month prior screen , Symptomatic chronic heart failure , history current evidence clinically significant cardiac arrhythmia and/or conduction abnormality &lt; 6 month prior screen except atrial fibrillation paroxysmal supraventricular tachycardia 2 . History Gilbert 's syndrome . 3 . Uncontrolled arterial hypertension despite medical treatment 4 . Prior therapy MEK inhibitor 5 . History current evidence retinal vein occlusion ( RVO ) current risk factor RVO ( e.g . uncontrolled glaucoma ocular hypertension , history hyperviscosity hypercoagulability syndrome ) 6 . History retinal degenerative disease ; 7 . Patients washout period &lt; 6 week last dose ipilimumab immunotherapy 8 . Known positive serology HIV , active hepatitis B , and/or active hepatitis C infection 9 . Patients neuromuscular disorder associate elevated CK ( e.g. , inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) 10 . Patients plan embark new strenuous exercise regimen first dose study treatment . Muscular activity , strenuous exercise , result significant increase plasma CK level avoid MEK162 treatment 11 . Patients currently receive treatment strong CYP3A4 inhibitor discontinue treatment switch different medication prior start study drug exclude study entry . Strong CYP3A4 inhibitor include follow medication : itraconazole , ketoconazole , miconazole , voriconazole ; amprenavir , atazanavir , fosamprenavir , indinavir , nelfinavir , ritonavir ; ciprofloxacin , clarithromycin , diclofenac , doxycycline , enoxacin , isoniazid , ketamine , nefazodone , nicardipine , propofol , quinidine , telithromycin . 12 . Patients receive treatment medication potential prolong QT interval discontinue treatment switch different medication prior start study drug exclude study entry . A list antiarrhythmic drug drug may prolong QT interval add protocol section 8.5 ( page 53 ) . 13 . Impaired gastrointestinal ( GI ) function active GI disease may significantly alter absorption study drug opinion treat physician ( e.g. , active ulcerative disease , uncontrolled nausea , uncontrolled vomiting , uncontrolled diarrhea , active malabsorption syndrome , small bowel resection within last 1 year gastric bypass surgery within last 1 year ) . 14 . Another active primary malignant disease , require systemic treatment ( chemotherapy radiation ) 15 . History significant congenital acquire bleed disorder unrelated cancer 16 . Major surgery within 4 week prior Day 1 study recover prior surgery . 17 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human chorionic gonadotropin ( hCG ) laboratory test 18 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception throughout study 3 month study drug discontinuation . Highly effective method contraception define . 19 . Patients eligible , willing able receive allogeneic stem cell transplant within 6 week eligible . 20 . Sexually active male unless use condom intercourse take drug 3 month stop treatment father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid ; 21 . History noncompliance medical regimen inability grant consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Advanced phase chronic myeloid leukemia</keyword>
	<keyword>refractory chronic phase chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Accelerated phase</keyword>
	<keyword>( AP )</keyword>
	<keyword>Blast phase</keyword>
	<keyword>( BP )</keyword>
	<keyword>Philadelphia-positive acute leukemia</keyword>
	<keyword>MEK-162</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>AMN107</keyword>
	<keyword>Tasigna</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
</DOC>